Belvedere Trading’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Belvedere Trading’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,400	Closed	-$101K	–	973
2024 Q1	$101K	Sell	2,400 -800	-25%	-$33.6K	﹤0.01%	442
2023 Q4	$136K	Buy	+3,200	New	+$92K	﹤0.01%	409
2022 Q1	–	Sell	-12,500	Closed	-$316K	–	669
2021 Q4	$316K	Buy	+12,500	New	+$441K	0.01%	147
2021 Q3	–	Sell	-26,800	Closed	-$602K	–	624
2021 Q2	$602K	Buy	+26,800	New	+$384K	0.04%	90

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Belvedere Trading's CERE Position: Q2 2024 in Review

Belvedere Trading sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 5,001 shares — an estimated $211K sold.

Belvedere Trading first reported a position in CERE in Q4 2023 and held it in 2 quarters. The position peaked at $265K in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

Belvedere Trading reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Belvedere Trading sold 5,001 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $211K.
Belvedere Trading first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
Belvedere Trading's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $265K in Q4 2023.
231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.